Gilead files US marketing application for remdesivir

The treatment has got the U.S. health regulator’s approval for emergency use in hospitalized patients with severe COVID-19

Gilead Sciences Inc said on Monday it has filed a marketing application with the U.S. Food and Drug Administration for its experimental COVID-19 drug remdesivir.

Continue Reading Below

The antiviral drug, to be available under the brand name Veklury, is one of the few treatments to have shown to be effective against the respiratory illness.

GET FOX BUSINESS ON THE GO BY CLICKING HERE

The treatment has got the U.S. health regulator’s approval for emergency use in hospitalized patients with severe COVID-19.

The marketing application is supported by data from two late-stage human trials conducted by Gilead and another late-stage trial by the National Institute of Allergy and Infectious Diseases, the company said.

CLICK HERE TO READ MORE ON FOX BUSINESS

The drug has been at the forefront in the fight against the respiratory illness after the intravenously administered medicine helped shorten hospital recovery times in a U.S. trial.

Remdesivir has been approved by multiple regulatory authorities around the world, including in the European Union and Japan.